Blog

  • Africa CDC and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa – Africa CDC

    Africa CDC and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa – Africa CDC

    ADDIS ABABA/BRUSSELS | 31 July 2025 — The Africa Centres for Disease Control and Prevention (Africa CDC) and the European Commission today announced the launch of the Partnership to Accelerate Mpox Testing and Sequencing in Africa (PAMTA), a landmark initiative to boost diagnostics and outbreak response capabilities in Mpox-affected African countries.

    Co-funded under the EU4Health 2024 Work Programme, PAMTA reflects the growing momentum of Africa–EU health cooperation and aims to reinforce the continent’s resilience against current and future health threats. The initiative will accelerate testing, sequencing, capacity building, and local manufacturing efforts for mpox and other priority pathogens across Africa through a €9.4 million to Africa CDC and the African Society for Laboratory Medicine (ASLM), managed by the European Health and Digital Executive Agency (HaDEA). The project officially began on 1 June 2025 and will be implemented over three years.

    Africa CDC Director General, H.E. Dr Jean Kaseya, welcomed the initiative as a timely and strategic intervention to close the diagnostic gap for Mpox and other outbreaks in Africa. “This partnership reflects our commitment to working with trusted partners to build agile and self-reliant public health systems across Africa. Together with the EU and our technical partners, we are setting a new benchmark for outbreak detection and response.”

    The PAMTA initiative focuses on four key objectives: scaling up Mpox testing with the goal of supporting over 150,000 tests across the continent; strengthening genomic sequencing capacity to track viral evolution and spread; building human resource capacity in molecular diagnostics, genomics, bioinformatics and data interpretation; and promoting the production and validation of locally developed testing kits within Africa.

    “PAMTA marks a historic milestone as the first initiative jointly signed between the European Commission and Africa CDC,” said Deputy Head of DG HERA, Laurent Muschel. “Building on HERA’s earlier donation of Mpox vaccines, this action enables a critical next step: strengthening diagnostic capacities as part of a broader medical countermeasures approach. It reflects our shared commitment to reinforcing epidemic preparedness across Africa — from vaccines to diagnostics, from innovation to manufacturing. This action shows that, together, the African Union and the European Union can deliver tangible results to protect lives.”

    The launch of PAMTA builds on broader efforts by the EU and its partners to address the Mpox outbreak. By mid-2025, more than 600,000 vaccine doses had been delivered to African countries through HERA and Team Europe. Simultaneously, research initiatives such as MPX-RESPONSE and EDCTP3 continue to explore new therapeutic options, while the Africa Pathogen Genomics Initiative (PGI)—also funded through EU4Health—is enhancing public health laboratory networks and genomic surveillance across the continent through public private partnerships.

    PAMTA marks a significant milestone in EU–Africa collaboration for health resilience. By supporting comprehensive diagnostics and fostering local innovation, the initiative is helping to lay a strong foundation for Africa’s long-term pandemic preparedness and response capabilities.

    #####

    NOTE TO EDITORS

    About Africa CDC

    The Africa Centres for Disease Control and Prevention (Africa CDC) is a public health agency of the African Union. It is autonomous and supports member states in strengthening health systems. It also helps improve disease surveillance, emergency response, and disease control. Learn more at: http://www.africacdc.org and connect with us on LinkedIn, Twitter, Facebook and YouTube

    About EU HERA

    HERA, established in September 2021, is a critical actor in strengthening Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies. 

    It is also a key pillar of the European Health Union, which the European Commission first put forward in November 2020 in response to the COVID-19 pandemic and as a means to prepare for future public health emergencies.

    MEDIA CONTACTS

    For Africa CDC

    Margaret Edwin
    Director of Communications and Public InformationEdwinM@africacdc.org

    Continue Reading

  • England to face ‘massive challenge’ without Leach: Lyon

    England to face ‘massive challenge’ without Leach: Lyon

    England have made their spin pecking order clear during their home summer, but Nathan Lyon believes they are overlooking their best

    Nathan Lyon says Jack Leach remains England’s best spinner, and warned the tourists would face a “massive challenge” without him in this summer’s Ashes Test series.

    Leach, who played a memorable role with the bat alongside Ben Stokes’ heroics at Headingley in the 2019 Ashes, last played for England on last year’s tour of Pakistan, where he returned 16 wickets at 31.43.

    That was a modest return compared to Pakistan’s Moman Ali and Sajid Khan, but far outperformed Shoaib Bashir, the 21-year-old who was once Leach’s understudy at Somerset.

    Since the Pakistan tour Bashir has become England’s first-choice spinner in series against New Zealand, Zimbabwe and India – until he suffered a series-ending finger injury at Lord’s.

    England then picked Liam Dawson for his first Test in eight years at Manchester, and have dropped him for the fifth Test starting tonight at The Oval, with Jacob Bethell returned to the playing XI as a part-time left-arm spin option alongside four quicks.

    Lyon, who played county cricket last winter at Lancashire, said England icon Jimmy Anderson had told him Brendon McCullum and his men saw Bashir as their version of Lyon.

    “I obviously played with Jimmy Anderson last year at Lancashire, and they basically said that they’re picking Bashir to do what I do,” Lyon said in Sydney where Westpac was unveiled as CA’s new principal partner as part of a landmark four-year agreement that will see Australian teams wear a red ‘W’ on their shirt fronts.

    “So I took a little bit of pride out of Jimmy respecting a little bit of what I’ve been able to do in my career.

    “But Bashir has been okay.

    “Jacob Bethell is playing this Test match (tonight at The Oval) and he looks like he’ll take up the spin bowling from Liam Dawson.

    “But in my eyes, Jack Leach is still their best spinner.”

    Leach, who missed the 2023 Ashes in England with a back injury, is currently the leading spinner in the County Championship’s first division this season, with 39 wickets at 24.76, twice taking six wickets in an innings.

    Leach claimed six wickets in the entire series on the 2021-22 Ashes tour, at 53.50.

    “It is a massive role, and it can be a massive challenge for people who haven’t done it in the past in these conditions,” Lyon said of spin bowling in Australia.

    “But I’m not going to let my secrets out so they come out and perform well out here.”

    Bashir, who looms as a likely inclusion in England’s Ashes touring party should he have recovered from the finger injury, does have some experience in Australian conditions, playing three four-day games on an England Lions tour in January.

    He leaked runs at 7.4 an over in his first innings and while offered tighter control in the second with 1-54 from 16 overs, he was outbowled in the match by WA spinner Corey Rocchiccioli.

    In the second match against the CA XI, Bashir returned 1-62 and 0-47, while in a match at NSW Blues’ base Cricket Central against Australia A he took 1-74 as England Lions suffered an innings defeat.

    “Our guys know how to play spin really well in this country,” said Lyon, who will enter the Ashes one wicket away from equalling Glenn McGrath’s record of 563 Test wickets.

    “That’s probably what helped me produce my skill to where it is at the moment.

    “I know I’ll keep trying getting better, and we’ll see how their spinners go.”

    Westpac have become Cricket Australia’s principal partner as part of a new four-year agreement, which will support cricket’s growth across all levels of the game

    Westpac’s logo will feature on the shirts of the Australian men’s and women’s teams for all matches played in Australia across Test, One-Day and T20 formats, as well as Australia A and Under-19s.

    The partnership will also provide opportunities for women and girls on and off the field, support initiatives aiding local clubs, volunteers and communities, and build on projects that ensure cricket is a sport for all.

    2025-26 NRMA Insurance Men’s Ashes

    First Test: November 21-25, Perth Stadium, 1.30pm AEDT

    Second Test: December 4-8, The Gabba, Brisbane (D/N), 3.30pm AEDT

    Third Test: December 17-21: Adelaide Oval, 11am AEDT

    Fourth Test: December 26-30: MCG, Melbourne, 10.30am AEDT

    Fifth Test: January 4-8: SCG, Sydney, 10.30am AEDT

    Continue Reading

  • World-first library of vaccine-enhancing adjuvants launches

    World-first library of vaccine-enhancing adjuvants launches

    • Pioneering library will serve as vaccine-adjuvant matchmaking service that creates more potent vaccines and speeds up the response to deadly disease outbreaks.
    • The library, funded by CEPI, will be hosted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
    • Adjuvants are added to vaccines to create stronger, longer-lasting immunity than vaccines alone.

    LONDON/OSLO, 31 JULY—Scientists have launched the first-ever library of adjuvants – substances that could boost the performance of vaccines tackling some of the world’s deadliest diseases.

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) will host a repository of 25 vaccine-enhancing adjuvants that can be ‘taken off the shelf’ and used in new vaccines being developed against epidemic and pandemic threats. This includes diseases like mpox, COVID-19 and Ebola, as well as a novel or as-yet-unidentified Disease X.

    The $2.5 million project—funded and led by the Coalition for Epidemic Preparedness Innovations (CEPI)—will act as a matchmaking service, helping vaccine developers select the best vaccine-adjuvant combination to make their vaccines more potent and effective. The adjuvants have been shared with the MHRA by leading research institutes and medical companies around the world for onward distribution.

    “Immune-boosting adjuvants have played a powerful role in transforming our response to deadly diseases over the past century. Yet, the COVID-19 pandemic shone a light on the challenges in accessing these vital ingredients, with the rights to adjuvants used in licensed COVID-19 vaccines held by only a handful of companies” explains Dr Richard Hatchett, CEO of CEPI. “Constrained supplies can result in an adjuvant getting paired with a vaccine based on what’s available at the time rather than what works best. This world-first library will fill the gap by matchmaking vaccines to a range of adjuvants to more rapidly identify the best combinations that could save lives and even stop a future pandemic in its tracks.”

    Following a pilot study, from late 2025 CEPI-backed vaccine developers will be able to request up to five adjuvant samples to combine with their vaccine candidates. Select CEPI-supported laboratories will then run preclinical tests on the vaccine-adjuvant pairings to screen which of the five combinations performs most strongly. The developer can use these data to guide whether to progress the successful vaccine-adjuvant pairing into clinical testing.

    In the case of an outbreak of a new Disease X, the adjuvant library could help quickly identify the top-performing vaccine-adjuvant pairings to contain the spread of the virus before it reaches pandemic proportions. This would support the 100 Days Mission, an ambitious goal to develop vaccines against newly emerging threats in as little as 100 days

     

    Boosting the power of vaccines

    Named after the Latin word “adjuvare”, meaning “to help” or “aid”, adjuvants are substances that are added in microscopic quantities to the majority of vaccines to enhance the immune response, creating stronger and longer lasting protection against infections than the vaccine alone. They are a key ingredient to help make vaccines more effective in certain age groups, such as babies or older adults, where a stronger immune response is needed.

    Adjuvants—which include ingredients like aluminium salts and plant compounds—are of particular importance in an escalating outbreak as they can reduce the dose required to elicit protection. This enables more vaccine doses to be produced at pace and made available to more people which can help to rapidly contain a fast-spreading threat. 

    “This is a major step forward in global efforts to prepare for future outbreaks. By giving vaccine developers fast access to a range of well-characterised adjuvants, the library will help speed up the development of more effective vaccines – particularly at the early stages of an emerging health threat,” said Dr Nicola Rose, Interim Executive Director of Science and Research at the MHRA, which is hosting the new global adjuvant library. “The MHRA is proud to host this new global resource, building on our long track record in supporting the safe and effective development of vaccines, particularly through the development and global distribution of biological standards. By enabling access to the adjuvant library, we are supporting developers in the timely identification of the best vaccine formulations, which can ultimately improve the effectiveness and quality of vaccines. Enabling developers to make effective vaccines available supports better disease protection for people worldwide.”

    By using the library, vaccine developers commit to using adjuvants on a non-exclusive basis so that multiple developers can have access to the same adjuvant supplies. In line with CEPI’s Equitable Access Policy, vaccine developers are encouraged to publish data on their vaccine and adjuvant pairings in open-access publications for all to benefit from the research. 

     

    ENDS

     

    Additional Quotes

    Keeley Foley, CEO, Access to Advanced Health Institute (AAHI), one of the adjuvant developers providing adjuvants to the library, said: “We are excited to partner with CEPI and MRHA on this groundbreaking adjuvant library, by contributing our innovative formulations, to accelerate safe and regulated vaccine development,  in the hope of providing underserved communities equitable access to life-saving vaccines worldwide.”

    Professor Jamie Triccas, Deputy Director, University of Sydney Infectious Diseases Institute (Sydney ID), a CEPI vaccine development partner taking part in the pilot study, said: “We are delighted to be part of CEPI’s pilot program to establish a global adjuvant library, enabling head-to-head testing of vaccine candidates with selected adjuvants. This is an important step toward accelerating next-generation vaccine development.”

    Dr. Maria Wurm, CEO of ExcellGene, a CEPI vaccine development partner taking part in the pilot study, said: “In 2020, our team was able to produce the first, ultra-pure CHO-cell provided SARS-CoV2 trimeric spike protein. We considered this a great achievement. We were then very fortunate to initiate a collaboration with Prof. Jamie Triccas and his great team and subsequently obtained generous funding from CEPI to push forward. This effort ultimately culminated then in the very first chimeric spike protein from coronaviruses which appeared to induce broad-ranging immunity in animals against the most critical virus variants. Providing this innovative material now to the world-first vaccine-enhancing library of adjuvants is a wonderful opportunity and a matter of great pride for our company”.  

     

    Notes to Editors 

    The adjuvants joining the library are provided by:

    • Allergy Therapeutics (UK)
    • Access to Advanced Health institute, AAHI (US) – 6 adjuvants
    • CHA Vaccine Institute (Korea)
    • Chengdu MaxVax (China) – 3 adjuvants
    • Clover Biopharmaceuticals (China)
    • Croda (UK/Denmark) – 2 adjuvants
    • The Global Health Drug Discovery Institute (China)
    • National Research Council Canada/Glycovax (Canada)
    • Jiangsu Recbio Technology (China) – 2 adjuvants
    • Panacea (India)
    • Parr Biotechnology (China) – 2 adjuvants
    • Shionogi & Co. (Japan)
    • Statens Serum Institute (Denmark) – 2 adjuvants
    • Sumitomo Pharma (Japan)

    Funding supports running the adjuvant library for an initial two-year period.

    Adjuvant developers applied to join the library following an Expression of Interest published by CEPI in 2023. CEPI selected the adjuvants to ensure that the library holds a diverse class of adjuvants based on their stage of development with the potential to be produced at scale for vaccine distribution in low- and middle-income countries. Most of the selected adjuvants have already been tested in preclinical toxicology studies, and many have already been used in human clinical trials.

    The service would first be available to CEPI-funded vaccine developers before potentially expanding more widely.

    For further information or to express your interest in using the Adjuvant Library, please email  [email protected]

     

    About CEPI 

    CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 60 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.

     

    About the Medicines and Healthcare products Regulatory Agency (MHRA)

    The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust, evidence-based judgements to ensure that the benefits justify any risks. The MHRA also plays a key role in supporting the development of safe and effective vaccines and treatments, through regulatory scientific research, physical and written standards and international collaboration.

    Continue Reading

  • Millions of evacuees return home as tsunami warnings lifted across Pacific

    Millions of evacuees return home as tsunami warnings lifted across Pacific




    (AFP) – After an 8.8-magnitude earthquake off the eastern Russian coast sparked tsunami warnings throughout the Pacific, millions of evacuees were allowed to return home on Wednesday, with only one total death resulting from Tuesday’s initial shock.

    Tsunami warnings were lifted across the Pacific rim on Wednesday, allowing millions of temporary evacuees to return home.

    After one of the strongest earthquakes ever recorded rattled Russia’s sparsely populated Far East, more than a dozen nations – from Japan to the United States to Ecuador – warned citizens to stay away from coastal regions.

    Storm surges of up to four metres (12 feet) were predicted for some parts of the Pacific, after the 8.8 quake struck off Russia’s Kamchatka peninsula.

    The tsunamis caused widespread disruption. Peru closed 65 of its 121 Pacific ports and authorities on Maui cancelled flights to and from the Hawaiian island.

    But fears of a catastrophe were not realised, with country after country lifting or downgrading warnings and telling coastal residents they could return.

    In Japan, almost two million people had been ordered to higher ground, before the warnings were downgraded or rescinded.

    The Fukushima nuclear plant in northeast Japan – destroyed by a huge quake and tsunami in 2011 – was temporarily evacuated.

    The only reported fatality was a woman killed while driving her car off a cliff in Japan as she tried to escape, local media reported.

    In Chile, authorities conducted what the Interior Ministry said was “perhaps the most massive evacuation ever carried out in our country” – with 1.4 million people ordered to high ground.

    Chilean authorities reported no damage or victims and registered waves of just 60 centimeters (two feet) on the country’s north coast.

    In the Galapagos Islands, where waves of up to three meters were expected, there was relief as the Ecuadoran navy’s oceanographic institute said the danger had passed.

    Locals reported the sea level falling and then rising suddenly, a phenomenon which is commonly seen with the arrival of a tsunami.

    But only a surge of just over a meter was reported, causing no damage.

    “Everything is calm, I’m going back to work. The restaurants are reopening and the places tourists visit are also open again,” said 38-year-old Santa Cruz resident Isabel Grijalva.

    Earlier national parks were closed, schools were shuttered, loudspeakers blared warnings and tourists were spirited off sightseeing boats and onto the safety of land.

    The worst damage was seen in Russia, where a tsunami crashed through the port of Severo-Kurilsk and submerged the local fishing plant, officials said.

    Russian state television footage showed buildings and debris swept into the sea.

    The surge of water reached as far as the town’s World War II monument about 400 meters from the shoreline, said Mayor Alexander Ovsyannikov.

    The initial quake also caused limited damage and only light injuries, despite being the strongest since 2011, when 15,000 people were killed in Japan.

    Russian scientists reported that the Klyuchevskoy volcano erupted shortly after the earthquake.

    “Red-hot lava is observed flowing down the western slope. There is a powerful glow above the volcano and explosions,” said Russia’s Geophysical Survey.

    Pacific alerts

    Wednesday’s quake was the strongest in the Kamchatka region since 1952, the regional seismic monitoring service said, warning of aftershocks of up to 7.5 magnitude.

    The US Geological Survey said the quake was one of the 10 strongest tremors recorded since 1900.

    It was followed by dozens of aftershocks that further shook the Russian Far East, including one of 6.9 magnitude.

    The USGS said there was a 59 percent chance of an aftershock of more than 7.0 magnitude in the next week. 


    Related Topics



    Subscribe Dunya News on YouTube

    ‘ ; r_text[1] = ” ; r_text[2] = ” ; r_text[3] = ” ; r_text[4] = ” ; r_text[5] = ” ; r_text[6] = ” ; var i = Math.floor(r_text.length * Math.random()); document.write(r_text[i]);

    Continue Reading

  • Statement Oliver Zipse, Chairman of the Board of Management of BMW AG, Conference Call Half-Year Report to 30 June 2025

    Statement Oliver Zipse, Chairman of the Board of Management of BMW AG, Conference Call Half-Year Report to 30 June 2025

    – Check against delivery –

     

    Ladies and Gentlemen,

    Good morning.

     

    Thanks to the strength and foresight of our strategy, our attractive
    product portfolio and our global team and operations, the BMW Group is
    built to weather various conditions.

     

    This is what separates us from the competition. And it underscores
    that there is not ONE automotive industry – major players are
    currently performing quite differently.

     

    Through the first half-year, our sales performance demonstrates the
    appeal of our global brands and the ongoing success of our broad
    technological approach.

     

    After confirming our original guidance from our Annual Conference
    after the first quarter results, we remain on track with our financial
    targets for the year – despite ongoing tariff uncertainty and
    fluctuations in the Chinese market.

     

    Unpredictability is a longstanding feature of the auto industry and
    is the norm in today’s business environment. What is decisive is how
    you deal with it. Because global success is rather predicated on your
    ability to anticipate developments and to respond rationally and efficiently.

     

    That is fundamental to the BMW Group. And we are building upon our
    leading position in the industry.

     

    The overall global automotive market is growing. We are always ready
    to profitably gain market share wherever individual market conditions
    allow. As dynamics in the industry shift, we know exactly where we are
    placed with our premium brands and where we can pursue opportunities –
    maintaining a healthy balance of value and volume.

     

    Over many decades, we have built up a comprehensive and balanced
    network of sales, production and supply chain operations spanning the
    major regions. This makes us one of the few truly global players in
    the industry and our deep roots in global markets offer us many advantages.

     

    First, they allow us to tap into leading-edge developments in the
    individual markets and understand specific customer needs. Our ties to
    research universities, our R&D network and IT hubs and our network
    of local tech partners enable us to leverage key competencies from
    individual markets for our global products and strategy.

     

    Second, through our extensive footprint in key markets, we remain
    resilient in the face of geopolitical instability and ever-increasing regulation.

     

    Finally, our strong ties also allow us to engage in direct
    discussions with key political decision-makers, who value our
    perspective. Here, it is not just about our individual interests, but
    rather finding solutions for customers worldwide and driving shared
    economic prosperity.

     

    The BMW Group welcomes the fundamental agreement between the European
    Union and the United States to reduce tariffs on both sides of the
    Atlantic. It’s now important to quickly finalize and implement the
    agreed measures.

     

    We will continue to advocate for trade between the EU and the US not
    be hindered by import tariffs. The currently agreed US tariffs also
    burden European exports, affecting consumers and globally operating
    companies. Therefore, we urge both sides to continue working towards
    market openness and the convergence of technical regulations.

     

    Through our global production network and supply chains, we maintain
    high flexibility to respond to fluctuations. Our production plants are
    attuned to market demand, allowing us to achieve capacity utilization
    above the industry standards.

     

    At our largest single plant in Spartanburg in the United States, for
    example, we produce over 400,000 vehicles annually. Over half of which
    serve the local market and half of which we export. Across the United
    States we have created extensive value chains as well as a competency
    hub for our global X Family of vehicles in Spartanburg, which remain
    in high demand across the entire globe.

     

    BMW made in America and sold to the world.

    This combination of leveraging the competitive advantage of the US
    market in SUVs with BMW’s brand strength allows us to develop products
    which speak to customers’ needs in markets worldwide.

     

    For the current financial year, our sales results continued into Q2
    in line with our expectations, as conditions continue to vary from
    market to market. In Q2, we saw a sequential improvement from Q1.

     

    Outside of China, all three of our major sales regions posted growth.

    Group sales in these markets combined to grow by 6.3% through the
    first six months of the year.

     

    Group sales in Europe grew overall by 10.2% in the second quarter and
    in Germany alone by over 10%, with growth in most markets outpacing
    the passenger vehicle market. Overall, the BMW brand increased its
    market share in Europe.

     

    Among the most successful BMW models were those in the business class
    segment. In the first half of the year, the BMW 5 Series saw growth of
    more than 40% worldwide compared to 2024.

    Other notable models that saw success included the BMW X2 models,
    which more than doubled sales through June.

     

    With the full availability of the new MINI family, the brand grew in
    all regions worldwide, including in China. In the first half of the
    year, more than one in three MINIs sold was a BEV.

     

    Rolls-Royce increased deliveries by nearly 10% in the second quarter,
    driven by strong sales from the Cullinan Series II*.

     

    Drivetrains and model variants across the portfolio continued to see
    success in Q2. BMW M sold nearly 106,000 vehicles through June, the
    best-ever first half-year for the brand.

     

    Sales of plug-in hybrid models from the BMW brand grew by almost 30%
    in the first six months. Our BEV models continue to be a fundamental
    pillar of our strategy. In the second quarter, we achieved an
    important milestone, with the delivery of our 1.5-millionth
    all-electric vehicle. Across the portfolio, we now offer more than 15
    all-electric models.

     

    In Europe, the Group’s BEV share reached 25%. With PHEVs included,
    the electrified share reached nearly 40%. Across all brands, BMW is
    the third best-selling BEV brand in Europe.

     

    While we are proud of our position as a leading BEV player, we know
    that the world is multi-dimensional.

     

    To meet consumer needs, especially in a product as complex and
    personal as a car, there is no single answer. Our Q2 results show that
    we can serve multiple preferences simultaneously: BEVs, PHEVs and our
    M models all achieved growth.

     

    The most effective strategic approach is to use all technologies to
    reduce CO2 emissions overall. We remain committed to the goals of the
    Paris Climate Agreement, while advocating for a review of the 2030 and
    2035 targets in the EU.

     

    To achieve these goals and create effective CO2 regulations, we must
    take a comprehensive view across the entire value chain. This would
    consider all emissions across the entire life cycle and not just
    tailpipe emissions: from the supply chain to the raw materials used in
    the car, the production process, the vehicle drive, energy used to
    power the vehicle, and finally to recycling.

     

    A dependency on a single technology can be damaging to an industry.
    Putting all your eggs in one basket is just poor asset allocation.

     

    Hydrogen, for example, offers Europe an opportunity to use our
    expertise and take the lead on an emerging technology that will
    contribute to our climate goals. And, unlike BEVs, without the need
    for large amounts of raw materials or battery technology which are not
    localizable at large scale in Europe.

     

    Beyond drivetrains, there is great potential with alternative fuels.
    There are more than 250 million vehicles in the EU, which could now
    immediately contribute to climate protection. But this requires a
    clear regulatory pathway and targeted investments in the ramp-up of
    all renewable fuels.

     

    Take HVO100 as an example. While it is already available in markets
    across Europe, tax schemes and the CO2 fleet targets need to recognize
    this renewable fueling option to incentivize customer adoption. This
    would help in scaling an alternative fuel that has a 90% CO2 saving
    compared to normal fuels and can already be accessed today. For OEMs
    and customers, this is also a cost-effective way to reduce emissions
    in the use phase.

     

    For Europe to maintain competitiveness and finance its future, we
    need to invest not only in new technologies, but also leverage our
    existing technologies, which can meet customer preferences and still
    contribute to climate targets.

     

    For the BMW Group, we are now just five weeks away from the next
    major innovation step, which our entire company has been fully focused
    on for many years now: the launch of the NEUE KLASSE.

     

    On September 5th, we will celebrate the world premiere of the all-new
    BMW iX3* at the IAA Mobility here in Munich.

     

    In June we hosted media representatives at the pre-drive event in
    Miramas in southern France. The initial feedback has been tremendous.

     

    We remain right on time with the launch, including at our new Plant
    in Debrecen. Construction also continues at our battery assembly
    facility in Irlbach-Straßkirchen.

     

    With the NEUE KLASSE, we are making great strides in all relevant
    technology fields – whether in electrification, digital user
    experience, driving dynamics or sustainability.

     

    The new BMW iX3 will be benchmark in the industry.

     

    The all-electric 6th generation powertrain will set standards in
    performance and efficiency:

    • powered by our battery cells developed in house, with 20% more
      energy density:
    • an electric range of up to 800 kilometers according to WLTP;
    • With 400-kilowatt maximum charging, customers will be able add
      over 350 kilometers to their vehicle’s range in just 10 minutes
      according to WLTP;
    • And with an energy consumption of 15 kilowatt hours per 100 kilometers.

    In addition, our revolutionary new iDrive will change the way the
    driver interacts with the car. With the BMW iDrive, we set an industry
    standard more than twenty years ago. After the reveal of the all-new
    Panoramic iDrive at CES in January, we are already seeing the industry
    follow our lead.

     

    With the technology clusters we have developed for the NEUE KLASSE,
    we will scale our advanced technologies across the portfolio. We will
    start in the core segment to build momentum quickly. This is simply
    smart economics.

     

    By 2027, we will bring 40 new models and model updates with NEUE
    KLASSE technology and design language on the road worldwide.

     

    Our technology cluster approach also allows us to integrate
    market-specific features and content. In our major sales regions, we
    have a variety of local solutions with leading partners. This allows
    us, for example, to further enhance the digital user experience as
    well as automated driving functions in our upcoming NEUE KLASSE models.

     

    In China, we are collaborating with Alibaba Banma to develop the next
    level of intuitive and conversational in-car voice interaction. We
    will also enhance our BMW Intelligent Personal Assistant with
    functionality from DeepSeek in our vehicles in China.

     

    In most other countries, the next-gen BMW intelligent personal
    assistant will be powered by large language model technology from
    Amazon Alexa.

     

    For driving assistance systems that meet local needs and regulations,
    we have also sought out partners in different geographies. Always
    following our philosophy in this area: smart, symbiotic and safe.

     

    Just two weeks ago, we announced a new partnership with Momenta, a
    leading Chinese ADAS technology provider. The partnership will focus
    on software development and integration for Chinese road-networks,
    traffic-conditions and user expectations, utilizing advanced AI
    algorithms and data driven development methods. We will launch the
    systems in China starting with our NEUE KLASSE.

     

    In other markets, we continue to build on our already very successful
    partnership with Qualcomm.

     

    These examples show how adaptive the NEUE KLASSE architecture is.

     

    With a software-defined vehicle, we maintain competency over all
    systems of the car and can roll them out to markets at the same time
    across the world. But we also are able to quickly integrate local tech
    stacks into our own ecosystem to give consumers access to innovations
    and features they are used to.

     

    And through backward integration of software solutions available for
    all aspects of the vehicle over the air, we will continuously enhance
    the customer experience.

     

    This is a huge advantage for us.

     

    Ladies and Gentlemen,

     

    Our consistent strategic approach and continued success is not a
    coincidence but the result of resolute, long-term planning and
    orientation. It is a multi-year process in every area of the company.

     

    This is what our stakeholders expect from us.

     

    The BMW brand is a promise. And we deliver on our promises.

     

    We continue to build upon the strong position we are in today.

    With the rollout of NEUE KLASSE technologies and products over the
    next two years, we will bring the company to a whole new level.

     

    Thank you.

     

    Continue Reading

  • IRSA releases 473,100 cusecs water

    IRSA releases 473,100 cusecs water

    – Advertisement –

    ISLAMABAD, Jul 31 (APP):Indus River System Authority (IRSA) on Thursday released 473,300 cusecs water from various rim stations with inflow of 534,700 cusecs.

    According to the data released by IRSA, the water level in River Indus at Tarbela Dam was 1538.00 feet which was 136.00 feet higher than the dead level of 1402.00 feet. Water inflow and outflow in the dam was recorded as 294,800 cusecs and 266,700 cusecs, respectively.

    The water level in River Jhelum at Mangla Dam was 1200.65 feet, which was 150.65 feet higher than its dead level of 1,050 feet. The inflow and outflow of water was recorded 40,500 cusecs and 7,000 cusecs, respectively.

    The release of water at Kalabagh, Taunsa, Guddu and Sukkur was recorded as 292,100, 282,000, 385,400 and 319,600 cusecs, respectively. Similarly, from River Kabul, a total of 32,300 cusecs of water released at Nowshera and 140,200 cusecs released from River Chenab at Marala.

    Continue Reading

  • Renal Autotransplantation for Complete Ureteral Avulsion Following Dil

    Renal Autotransplantation for Complete Ureteral Avulsion Following Dil

    Introduction

    Dilation and curettage is a widely utilized gynecological procedure for both diagnostic and therapeutic purposes, including the management of abnormal uterine bleeding, incomplete abortion, and retained products of conception. While generally regarded as safe, D&C carries a risk of significant complications, particularly when performed in the context of altered pelvic anatomy or with limited intraoperative visualization. Among these complications, uterine perforation is the most frequently encountered serious adverse event, with reported incidence rates of approximately 0.3% in premenopausal women and up to 2.6% in postmenopausal women undergoing D&C for non-obstetric indications. The risk is further elevated in pregnancy-related procedures, especially during management of postpartum hemorrhage or retained placental tissue, where perforation rates may reach as high as 5%.1,2

    Although uterine perforation itself may be clinically silent or self-limited, it can occasionally lead to injuries of adjacent pelvic organs, including the bowel, bladder, and ureters. Ureteral injury during D&C is exceptionally rare, with only a few cases documented in the literature.3–7 The ureters are particularly vulnerable during procedures complicated by lateral uterine perforation, especially in the presence of distorted pelvic anatomy due to previous surgeries, pelvic adhesions, or large fibroids. Ureteral avulsion, the most severe form of ureteral trauma, is characterized by complete detachment of the ureter and necessitates complex surgical reconstruction.3,4

    Conventional options for ureteral reconstruction include ureteroneocystostomy, ureteroureterostomy, and ileal ureteral substitution. However, in cases of extensive ureteral loss or complete avulsion where these techniques are not feasible, renal autotransplantation may serve as a definitive, nephron-sparing alternative. This technique involves nephrectomy followed by orthotopic or heterotopic reimplantation of the kidney with vascular and urinary tract reconstruction.8,9

    In this report, we present a rare case of complete ureteral avulsion following a D&C procedure, successfully managed with renal autotransplantation the first such case reported from our country. The case highlights the importance of early recognition and referral for advanced reconstructive options in the management of complex iatrogenic urological injuries.

    Case Report

    A 30-year-old Yemeni woman, gravida 2 para 1, with a body mass index (BMI) of 17.4 kg/m2, presented with a missed miscarriage at 18 weeks’ gestation. She underwent multiple unsuccessful D&C procedures for evacuation of retained fetal tissue. The final attempt was performed under general anesthesia in the operating theatre but was complicated by excessive vaginal bleeding and failure to remove the retained fetal head. The patient became hemodynamically unstable with pallor and a hemoglobin level of 6.9 g/dL, prompting an emergency exploratory laparotomy.

    Intraoperatively, approximately 1 liter of hemoperitoneum was evacuated. A large perforation on the left lateral aspect of the uterus was identified. Further exploration revealed complete avulsion of the left ureter at the The pelvi-ureteric junction (PUJ). Given the extent of injury, a temporary nephrostomy tube was placed for urinary diversion and preservation of renal function. The patient was stabilized and discharged in good condition on postoperative day 10 with plans for delayed reconstructive intervention.

    Four months later, the patient was referred to our center for definitive management. Preoperative laboratory testing revealed a serum creatinine level of 1.0 mg/dL and estimated glomerular filtration rate (eGFR) of 88 mL/min/1.73 m2, confirming preserved left renal function despite urinary diversion.

    On examination, her vital signs were within normal limits: blood pressure 100–110/90–100 mmHg and heart rate 80–90 bpm. Abdominal examination was unremarkable, and there was no tenderness or distention. Laboratory investigations, including renal function tests and complete blood count, were within normal ranges.

    Contrast-enhanced computed tomography urography demonstrated a normal right kidney and a hydronephrotic left kidney (Grade 2), with a consolidated renal pelvis and no identifiable left ureter distal to the PUJ. The nephrostomy tube was seen in place. Multidisciplinary consultation between urologists and vascular surgeons concluded that renal autotransplantation was the most appropriate reconstructive approach due to the complete absence of a viable ureteral segment.

    Surgical intervention was performed in two stages. Through a left anterior subcostal incision, the left kidney was mobilized. The Gerota’s fascia was opened, and the renal hilum was carefully dissected. Intraoperatively, no distal ureteral segment was identified. The renal artery and vein were meticulously isolated and transected, and the kidney was explanted. It was immediately flushed and perfused ex vivo with cold heparinized saline (Figure 1a).

    Figure 1 (a) Intraoperative image showing the explanted left kidney following nephrectomy and perfusion with cold heparinized saline solution prior to autotransplantation. (b) Restoration of blood flow in the transplanted kidney immediately after vascular anastomosis to the external iliac artery and vein in the right iliac fossa. (c) Construction of the Boari flap from the anterior bladder wall, formed into a tube to bridge the gap between the renal pelvis and urinary bladder.

    Simultaneously, a right-sided supra-inguinal reversed J-shaped incision was made to access the iliac vessels in the retroperitoneal space. The external iliac artery and vein were exposed and prepared for anastomosis. The renal vein and artery were anastomosed end-to-side to the external iliac vein and artery, respectively. After remove clamping, immediate restoration of perfusion and urine output was observed (Figure 1b). Total cold ischemia time was 12 minutes, and vascular anastomosis time was 10 minutes.

    Given the distance between the renal pelvis and urinary bladder, a Boari flap was fashioned from the anterolateral wall of the bladder to bridge the gap. A 2×4 cm flap was tabularized over a 12 Fr double-J stent and anastomosed to the renal pelvis (Figure 1c). The bladder defect was closed primarily. Drains were placed, and all incisions were closed in layers.

    Postoperative recovery was uneventful. Color Doppler ultrasound on postoperative day 1 revealed a well-perfused renal graft with normal corticomedullary differentiation, patent renal vessels, and a resistive index of 0.67. The surgical drain was removed on postoperative day 3, the Foley catheter on day 7, and antibiotics were discontinued on day 5. The patient was discharged on day 7 after a brief stay in the intensive care unit.

    At the two-month follow-up, intravenous pyelography confirmed bilateral renal function. The autotransplanted kidney showed prompt drainage into the bladder via a short reconstructed ureteral segment (Boari flap). Routine blood tests remained within normal parameters. The patient was scheduled for removal of the ureteric stent at three months post-transplantation. Follow-up care included biweekly renal function monitoring and blood pressure assessments. At the time of submission, she remained clinically stable with preserved renal function (serum creatinine 0.9 mg/dL, eGFR 92 mL/min/1.73 m2), and no evidence of obstruction or infection. Long-term imaging follow-up, including renal ultrasound and/or CT urography, was planned at six months to assess graft patency, renal drainage, and anatomical integrity.

    Discussion

    Ureteral injuries during gynecological procedures are uncommon but can have serious consequences if not promptly recognized and managed. The ureter is particularly vulnerable during procedures such as hysterectomy, oophorectomy, and D&C, especially in cases involving uterine perforation, distorted pelvic anatomy, or multiple surgical attempts. Iatrogenic ureteral injury during D&C is exceedingly rare, with only isolated case reports documented in the literature.6,7

    In the present case, multiple failed D&C attempts led to uterine perforation and complete avulsion of the left ureter at the PUJ. The injury went unrecognized until exploratory laparotomy for hemorrhagic shock revealed the extent of damage. Early placement of a nephrostomy tube was critical for urinary diversion, preservation of renal function, and stabilization prior to definitive reconstruction.

    Management of complete ureteral avulsion depends on the location and length of the defect, renal function, and availability of viable ureteral tissue. In cases where the ureteral loss is extensive, options include ileal ureteral substitution, ureterocalicostomy, transureteroureterostomy, or renal autotransplantation.3,4 Renal autotransplantation is typically reserved for complex or proximal ureteral injuries not amenable to other forms of reconstruction. It offers the advantage of relocating the kidney to the iliac fossa, where the shortened distance to the bladder allows for easier urinary drainage via ureteroneocystostomy or Boari flap.8,10

    In this case, imaging revealed complete ureteral loss, with no distal remnant. The left kidney was functioning and salvageable, warranting renal autotransplantation. Cold perfusion during bench surgery minimized ischemic injury, and end-to-side vascular anastomosis to the external iliac vessels allowed for reliable revascularization. The use of a Boari flap enabled tension-free urinary tract reconstruction.

    While renal autotransplantation has been previously reported as a solution for complex ureteral injuries, this case provides several unique contributions to the existing literature.11 First, it represents the first documented case of its kind in Yemen, highlighting the feasibility of performing highly complex reconstructive urological procedures in a resource-limited setting. Second, the case emphasizes the importance of multidisciplinary coordination between urology, vascular surgery, and anesthesia, which was essential to achieving a favorable outcome.

    Compared to similar cases reported in the literature (Neo et al,8 Tugmen et al,12 Kaymak et al,9 Consigliere et al13), the present case involved a complete PUJ avulsion following a gynecologic procedure—a rare etiology—and required the use of a Boari flap due to complete ureteral loss. This contrasts with other cases where distal ureter remnants allowed for primary ureteroneocystostomy. Additionally, our technique of cold perfusion, prompt anastomosis, and early functional recovery supports previously documented high success rates of renal autotransplantation when performed at experienced centers.

    To our knowledge, this is the first reported case of renal autotransplantation following complete ureteral avulsion in Yemen. This case highlights the importance of early recognition of ureteral injury, timely nephrostomy placement, multidisciplinary collaboration, and the role of renal autotransplantation as a definitive salvage procedure.

    Conclusion

    This case highlights the importance of considering renal autotransplantation as a definitive, organ-preserving surgical option in managing complex ureteral injuries, particularly when extensive ureteral loss precludes conventional reconstructive techniques. In experienced centers with multidisciplinary collaboration, renal autotransplantation offers excellent functional outcomes and should be considered in select patients, especially those with preserved renal function and no alternative options for urinary tract reconstruction. Early recognition of iatrogenic ureteral injury, prompt urinary diversion, and timely referral are critical to optimizing long-term outcomes.

    Data Sharing Statement

    The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

    Ethics Statement

    Institutional approval was not required for publication of this single case report according to the guidelines of Taiz University Faculty of Medicine, as the patient provided written informed consent.

    Informed Consent

    Written informed consent was obtained from the patient for publication of this case report and accompanying images.

    Acknowledgments

    The authors wish to thank the surgical, urology, and anesthesia teams at the Cardiovascular and Kidney Transplantation Centre, Taiz, Yemen, for their multidisciplinary support in the management of this case.

    Author Contributions

    All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

    Funding

    No external funding was received for the preparation or publication of this manuscript.

    Disclosure

    The authors declare no conflicts of interest related to this study.

    References

    1. Steinauer J, Patil R. Overview of pregnancy termination. UpToDate. 2022;2022(Cdc):1–43.

    2. Kakinuma T, Kakinuma K, Sakamoto Y, et al. Safety and efficacy of manual vacuum suction compared with conventional dilatation and sharp curettage and electric vacuum aspiration in surgical treatment of miscarriage: a randomized controlled trial. BMC Pregnancy Childbirth. 2020;20(1):695. doi:10.1186/s12884-020-03362-4

    3. Busque AA, Belzile E, Rodrigues J, Larouche M. Major perioperative complications of benign gynecologic procedures at a university-affiliated hospital. McGill J Med. 2022;21(1). doi:10.26443/mjm.v21i1.960

    4. Vakili B, Chesson RR, Kyle BL, et al. The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy. Am J Obstet Gynecol. 2005;192(5 Special Issue):1599–1604. doi:10.1016/j.ajog.2004.11.016

    5. Gustilo-Ashby AM, Jelovsek JE, Barber MD, Yoo EH, Paraiso MFR, Walters MD. The incidence of ureteral obstruction and the value of intraoperative cystoscopy during vaginal surgery for pelvic organ prolapse. Am J Obstet Gynecol. 2006;194(5):1478–1485.

    6. Park JH, Park JW, Song K, Jo MK. Ureteral injury in gynecologic surgery: a 5-year review in a community hospital. Korean J Urol. 2012;53(2):120–125. doi:10.4111/kju.2012.53.2.120

    7. Liapis A, Bakas P, Giannopoulos V, Creatsas G. Ureteral injuries during gynecological surgery. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(6):391–394. doi:10.1007/PL00004045

    8. Neo EN, Zulkifli Z, Sritharan S, Lee BC, Nazri J. Renal autotransplantation after an iatrogenic left ureteric injury. Med J Malaysia. 2007;62(2):164–165.

    9. Kaymak Ş, Özer MT, Demirbas S, Kaya E, Kozak O. Renal autotransplantation due to iatrogenic ureter injury: a case report. Ulus Travma Acil Cerrahi Derg. 2021;27(2):260–264.

    10. Hardy JD. High ureteral injuries: management by autotransplantation of the kidney. JAMA J Am Med Assoc. 1963;184(2):97–101. doi:10.1001/jama.1963.03700150051008

    11. Consigliere D, Tiong H. Renal autotransplantation following long segment iatrogenic ureteric injury. 2014.

    12. Tugmen C, Sert I, Zorlu F, Karaca C. An urgent renal autotransplantation in patient with ureteral avulsion. Int Med J Sifa Univ. 2015;2(3):52. doi:10.4103/2148-7731.166855

    13. Consigliere D, Tiong H, Zorilă GL, et al. Renal autotransplantation due to iatrogenic ureter injury: a case report. Ulus Travma Acil Cerrahi Derg. 2023;13(2):164–165.

    Continue Reading

  • Space Station Crew-11 astronauts set for launch

    Space Station Crew-11 astronauts set for launch

    Everything is set for the launch Crew-11 today (Thursday, 31 July) from Kennedy Space Center (KSC) at 12:09 Florida time (16:09 UTC) to the International Space Station (ISS). The weather outlook is currently 90 percent go and the weather in the recovery zone along the Atlantic Ocean is positive.

    This past Saturday a little after 1pm the four Crew-11 crewmembers, NASA astronauts Zena Cardman and Mike Fincke, JAXA astronaut Kimiya Yui and Roscosmos Cosmonaut Oleg Platonov arrived in Florida on a NASA Gulfstream jet from Houston. Early Sunday morning the Falcon-9 rocket with Crew Dragon capsule Endeavour was rolled out to the launchpad and raised in its vertical launch position.

    On Monday morning the crewmembers participated in a launch day dress rehearsal, simulating al the events that will take place on the actual launch day. After the conclusion of this test SpaceX prepared the Falcon-9 rocket for a static fire test, fuelling the rocket with propellant needed for the 10 second engine test.

    But the engine test was aborted at T-57 seconds due to a faulty sensor as NASA issued in a statement: “Monday’s test auto-aborted at T-57 seconds due to an error with the transporter erector’s cradle arm position indication. The arm functioned correctly and teams are reviewing the data”

    During Wednesday’s pre-launch media briefing from the Kennedy Space Center, SpaceX vice president Bill Gerstenmaier said that the sensor issue would have resulted in a launch scrub had it happened on the actual launch day. “It is good that we do these engine test,” Gerstenmaier added.

    So, a day late and after the sensor replacement, the 9 Merlin engines of the Falcon-9 rocket came to life Tuesday afternoon performing a good test. After the test fire however an engine controller on the number 5 engine had to be replaced as it was giving bad readings.

    On Wednesday NASA, SpaceX, Roscosmos and JAXA completed the Launch Readiness Review and mission managers polled that the were “GO” for launch on Thursday. Following the Launch Readiness Review a press conference was held at KSC.

    NASA Manager of the Commercial Crew Program Steve Stich, stated that if the launch di take place today docking to the ISS will take place on Saturday (2 August) some 39 hours after launch.

    Stich also hinted that Thursday was “the best time to launch” with weather for the back-up launch days will be less favourable.

    Once the Crew-11 astronauts have arrived on the ISS there will be a three-day handover with the Crew-10 astronauts before the latter begin their return to Earth on 6 August. NASA astronaut Jonny Kim will continue to help the Crew-11 astronauts familiarise themselves with life aboard the Space Station.

    During the six to eight month mission of Crew-11 (NASA and SpaceX are still reviewing data for a possible eight month mission, a decision will come soon said Steve Stich during Wednesday’s briefing) a new JAXA HTV-X cargo ship will dock to ISS and also the Cygnus NG-23 and SpaceX CRS-33 will visit.

    The international Space Station approaches a major milestone anniversary in October when it will mark 25 years of continuous human presence in space.

    # #

    Photo of Dragon crew capsule on its SpaceX launcher by Jacques van Oene.


    Continue Reading

  • Fred Vasseur continues with Scuderia Ferrari HP

    Fred Vasseur continues with Scuderia Ferrari HP

    Scuderia Ferrari HP is pleased to announce that it has extended, with a multiple-year contract, its agreement with Fred Vasseur, who will continue as Team Principal of Scuderia Ferrari HP for the coming Formula 1 seasons. 

    Fred joined the Scuderia at the beginning of 2023, bringing with him extensive motorsport experience and a proven ability to develop talent and build competitive teams across all levels of racing. Since then, he has laid a solid foundation with the ambition of returning Ferrari to the top of Formula 1.

    Renewing Fred’s contract reflects Ferrari’s determination to build on the foundations laid so far. His ability to lead under pressure, embrace innovation, and pursue performance aligns fully with Ferrari’s values and long-term ambitions.

    Under Fred’s leadership, Scuderia Ferrari HP is united, focused, and committed to continuous improvement. The trust placed in him reflects the team’s confidence in its strategic direction and reinforces a shared determination to deliver the results that Ferrari’s fans, drivers, and team members expect and deserve.

    Benedetto Vigna CEO Ferrari

    Today we want to recognize what has been built and commit to what still needs to be achieved. It reflects our trust in Fred’s leadership — a trust rooted in shared ambition, mutual expectations and clear responsibility. We move forward with determination and focus, united in our pursuit of the level of performance Ferrari has to aim for.

    Fred Vasseur Team Principal Scuderia Ferrari HP

    I’m grateful for the trust Ferrari continues to place in me. This renewal is not just a confirmation — it’s a challenge to keep progressing, to stay focused, and to deliver. Over the past 30 months, we’ve laid strong foundations, and now we must build on them with consistency and determination. We know what’s expected, and we’re all fully committed to meeting those expectations and taking the next step forward together.

     

     

    Continue Reading

  • Solar ‘eclipse of the century’ will happen in 2027

    Solar ‘eclipse of the century’ will happen in 2027



    Solar ‘eclipse of the century’ will happen in 2027

    The solar ‘eclipse of the century’ will take place on August 2, 2027, with an impressive duration and visibility.

    There is some misinformation circulating on social media that the longest solar eclipse will occur next month. No, there won’t be any solar eclipse in August 2025, and the news is completely wrong.

    The major solar eclipse creating buzz online is scheduled for August 2, 2027. The ‘eclipse of the century’ will last for 6 minutes and 23 seconds. It will be the longest solar eclipse visible from land between 1991 and 2114.

    During this astronomical event, the moon will block the sun completely. The moon will be closest to Earth and will appear larger. The Earth will be near its farthest point from the Sun, making the Sun appear a bit smaller.

    The path of the eclipse will be close to the equator, a region where the speed of the Moon’s shadow moves slowly across the Earth.

    The path of the totality, where the Sun will be completely overshadowed by the Moon, will stretch across 3 continents, which means it will cross the path of 11 countries. But the whole world will not go dark.

    There is scientific significance to this eclipse. It will be a great opportunity for the scientists to study the surface of the Sun: the Corona, coronal mass ejections, and solar flares.

    The ‘eclipse of the century’ will last for 6 minutes and 23 seconds
    The ‘eclipse of the century’ will last for 6 minutes and 23 seconds

    During this specific time, everyone should avoid directly looking at the Sun. The ISO-certified eclipse glasses are recommended to view the sky. Ordinary glasses or binoculars without a solar filter are not safe and cause eye damage.

    In comparison, a total solar eclipse occurred in the United States, Mexico, and Canada on April 8, 2024. The totality lasted for 4 minutes and 28 seconds.

    There will be a partial solar eclipse on September 21, 2025. It will be visible from New Zealand, Eastern Australia, Antarctica, and the South Pacific Ocean.

    What is a Solar and Lunar Eclipse?

    A Solar eclipse occurs when the Moon passes between the Sun and Earth. A Lunar eclipse occurs when the Earth passes between the Sun and the Moon. 

    Continue Reading